Skip to content
value.today

Manus Bio Inc.

Total raised
$184 M
6 rounds on record
Latest round
$11 M
Apr 2024
First round on record
Aug 2017
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Manus Bio Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2024$11 MNo. 6$10 to $50 million

Manus Bio Inc.: Raise no. 6, Apr 2024

Investors in this round

6 investors had bought by the notice of May 14, 2024: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Manus Bio Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Common Stock to be acquired upon exercise of option.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ajikumar Parayil Kumaran · Director, Executive Officer · Dr. Parayil is the Founder, President, and Chief Executive Officer of the Issuer.
  • Julio A. Ruiz Calderon · Executive Officer · Mr. Ruiz Calderon is the Interim Chief Financial Officer of the Issuer.
  • Alena A. Ivashenka · Director
  • Jean A. Nehme · Director
  • Michael A. Carlos · Director
  • Rick A. Gerson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ajikumar Parayil Kumaran, President of the Issuer. Source: SEC Form D, newest notice filed May 14, 2024. Read the notice at the SEC.

equity, optionsSEC
Aug 2021$21 MNo. 5$10 to $50 million

Manus Bio Inc.: Raise no. 5, Aug 2021

Investors in this round

14 investors had bought by the notice of May 31, 2023: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Manus Bio Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $22 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible promissory notes; Equity securities underlying convertible promissory notes.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ajikumar Parayil · Executive Officer, Director · Dr. Parayil is the Founder, President and Chief Executive Officer of the Issuer.
  • Jeremiah Hux · Executive Officer · Mr. Hux is the Chief Financial Officer of the Issuer.
  • Alena Ivashenka · Director
  • John Nehme · Director
  • Michael Carlos · Director
  • Rick Gerson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount includes the interest of 5% on the convertible promissory notes.”

Signed by Ajikumar Parayil, President & CEO of the Issuer. Source: SEC Form D, newest notice filed May 31, 2023. Read the notice at the SEC.

equity, debt, optionsSEC
Aug 2020$66 MNo. 4$50 to $250 million

Manus Bio Inc.: Raise no. 4, Aug 2020

Investors in this round

27 investors had bought by the notice of Nov 6, 2020: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Manus Bio Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$66 M of $80 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series B-3 Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ajikumar Parayil · Executive Officer, Director · Dr. Parayil is the Founder, President and Chief Executive Officer of the Issuer.
  • Christine Santos · Executive Officer · Dr. Santos is the Secretary and Chief Technology Officer of the Issuer.
  • Jeff Anderson · Executive Officer · Mr. Anderson is the Chief Operations Officer of the Issuer.
  • Paul Boni · Executive Officer · Mr. Boni is the Chief Financial Officer of the Issuer.
  • Bryon Alsberg · Director
  • Colin Gounden · Director
  • Gregory Stephanopoulos · Director
  • Michael Carlos · Director
  • Raymond Chang · Director
  • Zanna McFerson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ajikumar Parayil, President and CEO of the Issuer. Source: SEC Form D, newest notice filed Nov 6, 2020. Read the notice at the SEC.

equitySEC
Apr 2020$66 MNo. 3$50 to $250 million

Manus Bio Inc.: Raise no. 3, Apr 2020

Investors in this round

27 investors had bought by the notice of Nov 9, 2020: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Manus Bio Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$66 M of $80 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series B-3 Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ajikumar Parayil · Executive Officer, Director · Dr. Parayil is the Founder, President and Chief Executive Officer of the Issuer.
  • Christine Santos · Executive Officer · Dr. Santos is the Secretary and Chief Technology Officer of the Issuer.
  • Jeff Anderson · Executive Officer · Mr. Anderson is the Chief Operations Officer of the Issuer.
  • Paul Boni · Executive Officer · Mr. Boni is the Chief Financial Officer of the Issuer.
  • Bryon Alsberg · Director
  • Colin Gounden · Director
  • Gregory Stephanopoulos · Director
  • Michael Carlos · Director
  • Raymond Chang · Director
  • Zanna McFerson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ajikumar Parayil, President and CEO of the Issuer. Source: SEC Form D, newest notice filed Nov 9, 2020. Read the notice at the SEC.

equitySEC
Jun 2018$10 MNo. 2$10 to $50 million

Manus Bio Inc.: Raise no. 2, Jun 2018

Investors in this round

15 investors had bought by the notice of Jul 16, 2018: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Manus Bio Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $12 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Series A-1 Preferred Stock and Warrants to purchase Series A-1 Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ajikumar Parayil · Executive Officer, Director · Dr. Parayil is the Founder, President and Chief Executive Officer of the Issuer.
  • Christine Santos · Executive Officer · Dr. Santos is the Secretary and Chief Technology Officer of the Issuer.
  • Jeff Anderson · Executive Officer · Mr. Anderson is the Chief Operations Officer of the Issuer.
  • Paul Boni · Executive Officer · Mr. Boni is the Chief Financial Officer of the Issuer.
  • Bryon Alsberg · Director
  • Colin Gounden · Director
  • Gregory Stephanopoulos · Director
  • Michael Carlos · Director
  • Raymond Chang · Director
  • Zanna McFerson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ajikumar Parayil, President and Chief Executive Officer of the Issuer. Source: SEC Form D, newest notice filed Jul 16, 2018. Read the notice at the SEC.

equity, optionsSEC
Aug 2017$9 MNo. 1$2 to $10 million

Manus Bio Inc.: Raise no. 1, Aug 2017

Investors in this round

24 investors had bought by the notice of Dec 29, 2017: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Manus Bio Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $10 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ajikumar Parayil · Executive Officer, Director
  • Byron Alsberg · Director
  • Carsten Boers · Director
  • Colin Gounden · Director
  • Gregory Stephanopoulos · Director
  • Michael Carlos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ajikumar Parayil, President. Source: SEC Form D, newest notice filed Dec 29, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Manus Bio Inc. chose not to state its revenue in its newest notice of a funding round (May 2024).

    SEC Form D · May 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2024

That is all the official record says: Manus Bio Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Manus Bio Inc.
InvestorKindAmountRoundRoleSource
T. Rowe Price New Horizons Fund, Inc.Fund or asset manager$6 Mheldnot statedHolds Series ONE-6 shares (fund report, Jun 2026)SEC Form N-PORT
T. Rowe Price Health Sciences Fund, Inc.Fund or asset manager$4 Mheldnot statedHolds Series ONE-6 shares (fund report, Jun 2026)SEC Form N-PORT
T. Rowe Price Small-Cap Stock Fund, Inc.Fund or asset manager$2 Mheldnot statedHolds Series ONE-6 shares (fund report, Jun 2026)SEC Form N-PORT
T. Rowe Price Institutional Small-Cap Stock FundFund or asset manager$1 Mheldnot statedHolds Series ONE-6 shares (fund report, Jun 2026)SEC Form N-PORT
T. Rowe Price Health Sciences PortfolioFund or asset manager$0 Mheldnot statedHolds Series ONE-6 shares (fund report, Jun 2026)SEC Form N-PORT
T. Rowe Price Spectrum Moderate Growth Allocation FundFund or asset manager$0 Mheldnot statedHolds Series ONE-6 shares (fund report, May 2026)SEC Form N-PORT
T. Rowe Price Spectrum Moderate Allocation FundFund or asset manager$0 Mheldnot statedHolds Series ONE-6 shares (fund report, May 2026)SEC Form N-PORT
T. Rowe Price Spectrum Conservative Allocation FundFund or asset manager$0 Mheldnot statedHolds Series ONE-6 shares (fund report, May 2026)SEC Form N-PORT
T. Rowe Price Moderate Allocation PortfolioFund or asset managernot statednot statedHolds Series ONE-6 shares (fund report, Jun 2026)SEC Form N-PORT

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 27 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Manus Bio Inc.
NameRoleNamed in
Ajikumar Parayil KumaranDr. Parayil is the Founder, President, and Chief Executive Officer of the Issuer.May 2024
Julio A. Ruiz CalderonMr. Ruiz Calderon is the Interim Chief Financial Officer of the Issuer.May 2024
Ajikumar ParayilDr. Parayil is the Founder, President and Chief Executive Officer of the Issuer.May 2023
Jeremiah HuxMr. Hux is the Chief Financial Officer of the Issuer.May 2023
Christine SantosDr. Santos is the Secretary and Chief Technology Officer of the Issuer.Nov 2020
Jeff AndersonMr. Anderson is the Chief Operations Officer of the Issuer.Nov 2020
Paul BoniMr. Boni is the Chief Financial Officer of the Issuer.Nov 2020
Ajikumar Parayil KumaranDr. Parayil is the Founder, President, and Chief Executive Officer of the Issuer.May 2024
Alena A. IvashenkaDirectorMay 2024
Jean A. NehmeDirectorMay 2024
Michael A. CarlosDirectorMay 2024
Rick A. GersonDirectorMay 2024
Ajikumar ParayilDr. Parayil is the Founder, President and Chief Executive Officer of the Issuer.May 2023
Alena IvashenkaDirectorMay 2023
John NehmeDirectorMay 2023
Michael CarlosDirectorMay 2023
Rick GersonDirectorMay 2023
Bryon AlsbergDirectorNov 2020
Colin GoundenDirectorNov 2020
Gregory StephanopoulosDirectorNov 2020
Raymond ChangDirectorNov 2020
Zanna McFersonDirectorNov 2020
Byron AlsbergDirectorDec 2017
Carsten BoersDirectorDec 2017